Shishido Stephanie N, Ghoreifi Alireza, Sayeed Salmaan, Courcoubetis George, Huang Amy, Ye Brandon, Mrutyunjaya Sankalp, Gill Inderbir S, Kuhn Peter, Mason Jeremy, Djaladat Hooman
Convergent Science Institute in Cancer, Michelson Center for Convergent Bioscience, University of Southern California, Los Angeles, CA 90089, USA.
Catherine and Joseph Aresty Department of Urology, Institute of Urology, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA.
Cancers (Basel). 2022 Jun 18;14(12):3007. doi: 10.3390/cancers14123007.
Urothelial carcinomas (UCs) are a broad and heterogeneous group of malignancies, with the prevalence of upper tract urothelial carcinoma (UTUC) being rare, accounting for only 5-10% of total malignancies. There is a need for additional toolsets to assist the current clinical paradigm of care for patients with UTUC. As a non-invasive tool for the discovery of cancer-related biomarkers, the liquid biopsy has the potential to represent the complex process of tumorigenesis and metastasis. Herein, we show the efficacy of the liquid biopsy as a source of biomarkers for detecting UTUC. Using the third-generation high-definition single-cell assay (HDSCA3.0) workflow, we investigate liquid biopsy samples collected from patients with UTUC and normal donors (NDs) to provide critical information regarding the molecular and morphological characteristics of circulating rare events. We document several important findings from the liquid biopsy analysis of patients diagnosed with UTUC prior to surgery: (1) Large extracellular vesicles (LEVs) and circulating tumor cells (CTCs) are detectable in the peripheral blood. (2) The rare-event profile is highly heterogeneous. (3) Clinical data elements correlate with liquid biopsy analytes. Overall, this study provides evidence for the efficacy of the liquid biopsy in understanding the biology of UTUC with the future intent of informing clinical decision making, ultimately improving patient outcomes.
尿路上皮癌(UCs)是一类广泛且异质性的恶性肿瘤,上尿路尿路上皮癌(UTUC)的患病率较低,仅占全部恶性肿瘤的5%-10%。需要更多的工具集来辅助当前针对UTUC患者的临床护理模式。作为一种用于发现癌症相关生物标志物的非侵入性工具,液体活检有潜力展现肿瘤发生和转移的复杂过程。在此,我们展示了液体活检作为检测UTUC生物标志物来源的有效性。使用第三代高清单细胞分析(HDSCA3.0)工作流程,我们研究了从UTUC患者和正常供体(NDs)收集的液体活检样本,以提供有关循环罕见事件的分子和形态特征的关键信息。我们记录了对术前诊断为UTUC的患者进行液体活检分析的几个重要发现:(1)外周血中可检测到大型细胞外囊泡(LEV)和循环肿瘤细胞(CTC)。(2)罕见事件谱高度异质性。(3)临床数据元素与液体活检分析物相关。总体而言,本研究为液体活检在理解UTUC生物学方面的有效性提供了证据,其未来目的是为临床决策提供信息,最终改善患者预后。